NCT02882126 - An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension | Biotech Hunter

Timeline

Start Date

June 30, 2017

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Subcutaneous Treprostinil

Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.

Trial Locations (10)

100020

Beijing Chao-Yang Hospital, Beijing

100029

Beijing Anzhen Hospital, Capital Medical University, Beijing

100032

Peking Union Medical College Hospital, Beijing

100037

Fu Wai Hospital, Beijing

100038

Beijing Shijitan Hospital, Beijing

200032

Zhongshan Hospital affiliated with Fudan University, Shanghai

200433

Shanghai Pulmonary Hospital, Shanghai

410008

Xiangya Hospital Centre South University, Changsha

430022

Wuhan Asia Heart Hospital, Wuhan

510080

Guangdong General Hospital, Guangzhou